DoD FY11 Prostate Cancer Population-Based Research Award

The summary for the DoD FY11 Prostate Cancer Population-Based Research Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

DoD FY11 Prostate Cancer Population-Based Research Award: The PCRP Population-Based Research Award mechanism was first offered as the Population-Based Idea Development Award in FY09. Since then, 51 applications have been received, and 3 have been recommended for funding. The Population-Based Research Award mechanism supports high-impact, population-based approaches to prostate cancer research. Applications should clearly demonstrate the potential of the study to contribute significantly to the elimination of death and suffering from prostate cancer. The overall goal of this award is to generate unique information and/or tools that can only be achieved from the perspective of systematic studies of a defined patient population. A robust statistical plan is required and should be supported with requisite statistical expertise in the study team. All applications for the Population-Based Research Award are highly recommended to address one of the FY11 PCRP overarching challenges. The PCRP seeks to fund projects from the wide spectrum of basic to clinical research; however, if the proposed project does not address one of the overarching challenges, the application should provide a description to justify how the project will nevertheless address a critical need in the field of prostate cancer research and/or patient care. Applications may propose retrospective, prospective, case control, cohort, or other population-based study designs (including the use of biospecimens and data from established retrospective databases), provided the proposed sample is of sufficient size to demonstrate statistical significance. The study should address a well developed hypothesis that is conceptually sound and specific for prostate cancer. The statistical expertise of the study team should be clearly described and evident in the study plan. Applicants are expected to provide documentation demonstrating access to, and ability to recruit, the appropriate population(s) or patient samples in numbers sufficient to achieve statistical significance. Research proposed under the Population-Based Research Award may include the following topic areas: Biomarkers Predictors of response to therapy Disease aggressiveness Epidemiology/Public Health Genomics (germline or somatic) Health disparity Molecular genetics Risk prediction Research involving human subject use is permitted under this funding opportunity, but is restricted to studies without clinical trials; however, correlative studies, including studies with populations from existing clinical trials, are allowed. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. For more information on clinical research, a Human Subject Resource Document is provided at https://cdmrp.org/Program_Announcements_and_Forms/. Principal Investigators (PIs) seeking funding for a clinical trial should consider submitting an application for the FY11 PCRP Clinical Trial Award.